AI Article Synopsis
- Cognitive dysfunction is a key symptom of Alzheimer's disease (AD), and high levels of orexin in the cerebrospinal fluid are linked to the disease's progression.
- A study involving the OX1R antagonist SB-334867 on 3xTg-AD mice revealed that blocking OX1R worsened memory and synaptic function while increasing harmful Aβ and p-tau levels.
- The findings suggest that OX1R plays a significant role in cognitive functioning in AD, with negative effects associated with decreased PSD-95 and impaired long-term potentiation.
Article Abstract
Cognitive dysfunction is the main clinical manifestation of Alzheimer's disease (AD). Previous research found that elevated orexin level in the cerebrospinal fluid was closely related to the course of AD, and orexin-A treatment could increase amyloid β protein (Aβ) deposition and aggravate spatial memory impairment in APP/PS1 mice. Furthermore, recent research found that dual orexin receptor (OXR) antagonist might affect Aβ level and cognitive dysfunction in AD, but the effects of OX1R or OX2R alone is unreported until now. Considering that OX1R is highly expressed in the hippocampus and plays important roles in learning and memory, the effects of OX1R in AD cognitive dysfunction and its possible mechanism should be investigated. In the present study, selective OX1R antagonist SB-334867 was used to block OX1R. Then, different behavioral tests were performed to observe the effects of OX1R blockade on cognitive function of 3xTg-AD mice exhibited both Aβ and tau pathology, in vivo electrophysiological recording and western blot were used to investigate the potential mechanism. The results showed that chronic OX1R blockade aggravated the impairments of short-term working memory, long-term spatial memory and synaptic plasticity in 9-month-old female 3xTg-AD mice, increased levels of soluble Aβ oligomers and p-tau, and decreased PSD-95 expression in the hippocampus of 3xTg-AD mice. These results indicate that the detrimental effects of SB-334867 on cognitive behaviors in 3xTg-AD mice are closely related to the decrease of PSD-95 and depression of in vivo long-term potentiation (LTP) caused by increased Aβ oligomers and p-tau.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbr.2022.114171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut microbiota dysbiosis in Alzheimer's disease (AD): Insights from human clinical studies and the mouse AD models.
Physiol Behav
December 2024
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA; Deptment of Neuroscience & Regenerative Medicine, Augusta, GA 30912, USA; College of Agriculture, Food, and Natural Resources, Prairie View A&M University, Prairie View, TX 77446, USA; Centre for Healthy Aging, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Cell Biology and Anatomy, Medical College of Georgia, Augusta University, GA, USA; Department of Orthopedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address:
Alzheimer's Disease (AD) is a debilitating neurocognitive disorder with an unclear underlying mechanism. Recent studies have implicated gut microbiota dysbiosis with the onset and progression of AD. The connection between gut microbiota and AD can significantly affect the prevention and treatment of AD patients.
View Article and Find Full Text PDFCombining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease.
Biomed Pharmacother
December 2024
Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI United States.
Behavioral testing is an essential tool for evaluating cognitive function and dysfunction in preclinical research models. This is of special importance in the study of neurological disorders such as Alzheimer's disease. However, the reproducibility of classic behavioral assays is frequently compromised by interstudy variation, leading to ambiguous conclusions about the behavioral markers characterizing the disease.
View Article and Find Full Text PDFGlyphosate exposure exacerbates neuroinflammation and Alzheimer's disease-like pathology despite a 6-month recovery period in mice.
J Neuroinflammation
December 2024
Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Article Synopsis
- Glyphosate usage has risen significantly in the U.S. since 1996, with research showing it can accumulate in the brain and invoke neuroinflammation, potentially influencing neurodegenerative disorders like Alzheimer's Disease (AD).
- The study involved giving varied doses of glyphosate to both Alzheimer's model mice and control mice, revealing that glyphosate and its metabolite remained detectable in brain tissue even after a recovery period.
- Results indicated that glyphosate exposure led to worsened cognitive function in AD mice, along with significant increases in brain plaque formation, tau protein abnormalities, and persistent inflammatory markers in both mouse groups.
A preclinical and phase I clinical study of ex vivo-expanded amyloid beta-specific human regulatory T cells in Alzheimer's disease.
Biomed Pharmacother
December 2024
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea. Electronic address:
Article Synopsis
- Advances in the development of amyloid β-specific human Tregs (Aβ-hTreg) show promise for treating Alzheimer's disease (AD), despite challenges with Treg selection and expansion.
- A successful ex vivo expansion method was established, leading to a phase 1 clinical trial with six Alzheimer's patients that evaluated the safety and initial efficacy of Aβ-hTreg.
- Results indicated improved cognitive function and safety of the treatment in mice, while no significant toxicity was observed in patients, suggesting a potential pathway for future AD clinical trials.
Spatial and planar profiling of Rac1/Cdc42 signaling in Alzheimer's disease brain.
J Alzheimers Dis
December 2024
Department of Anatomy and Cell Biology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
Article Synopsis
- - The study focuses on the dysregulation of small GTPases Rac1 and Cdc42 in Alzheimer's disease (AD), which are important for maintaining synaptic structures and could be potential therapeutic targets.
- - Researchers used specific antibodies to assess the activity levels of Rac1/Cdc42 and their downstream effects in brains from a triple transgenic mouse model and human AD samples.
- - Results showed that Rac1/Cdc42 activity changes vary across different regions of the brain, with decreased activity in certain areas of AD-affected mice and variations also noted in human AD samples, indicating a complex relationship with the disease's progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!